

Pneumococcal Vaccines for Adults

There are now two FDA approved pneumococcal vaccines for use in adults. Pneumovax (PPSV23) has been recommended for use in adults since 1983. In June, 2012 the Advisory Committee on Immunization Practices (ACIP) recommended the routine use of Prevnar (PCV13) for a limited population. This includes adults 19 years and older with immunocompromising conditions, functional or anatomic asplenia, cerebrospinal fluid leaks or cochlear implants.

Recommendations

Table 1. Medical conditions or other indications for administration of 13-valent pneumococcal conjugate vaccine (PCV13), as well as indications for 23-valent pneumococcal polysaccharide vaccine (PPSV23) administration and revaccination for adults aged 19-64 years. <http://www.cdc.gov/vaccines/recs/provisional/downloads/pcv13-adults-ic.pdf>

Risk Group	Underlying Medical Condition	PCV13	PPSV23	
		Recommended	Recommended	Revaccination at 5 years
Immunocompetent persons	Chronic heart disease		X	
	Chronic lung disease		X	
	Diabetes mellitus		X	
	CSF leaks	X	X	
	Cochlear implants	X	X	
	Alcoholism		X	
	Chronic liver disease		X	
	Cigarette smoking		X	
Persons with functional or anatomic asplenia	Sickle cell disease/other hemaglobinopathies	X	X	X
	Congenital or acquired asplenia	X	X	X
Immunocompromised persons	Congenital or acquired immunodeficiencies	X	X	X
	HIV infection	X	X	X
	Chronic renal failure	X	X	X
	Nephrotic syndrome	X	X	X
	Leukemia	X	X	X
	Lymphoma	X	X	X
	Hodgkin disease	X	X	X
	Generalized malignancy	X	X	X
	Iatrogenic immunosuppression	X	X	X
	Solid organ transplant	X	X	X
	Multiple myeloma	X	X	X

Draft